However, combining radiotherapy as the standard-of-care with IRF5/IKKβ NP injections substantially reduced tumor growth and more than doubled the survival of treated mice compared to the PBS control group (52 days versus 25 days, respectively; Fig. 9e, f). The gene discussed is IKBKB; the disease is neoplasm.